Common Contracts
5 similar Executive Employment Agreement contracts by Roivant Sciences Ltd.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 9th, 2024 • Roivant Sciences Ltd. • Pharmaceutical preparations • New York
THIS EMPLOYMENT AGREEMENT (together with all exhibits hereto, this “Agreement”) is hereby entered into as of June 5, 2023 (the “Effective Date”), by and between Roivant Sciences, Inc., a Delaware corporation (the “ Company”), and Rakhi Kumar, an individual (“Executive”) (hereinafter collectively referred to as the “Parties”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 9th, 2024 • Roivant Sciences Ltd. • Pharmaceutical preparations • New York
THIS EMPLOYMENT AGREEMENT (together with all exhibits hereto, this “Agreement”) is hereby entered into as of August 31, 2021, by and between Roivant Sciences, Inc., a Delaware corporation (the “Company”), and Richard Pulik, an individual (“Executive”) (hereinafter collectively referred to as the “Parties”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 14th, 2021 • Roivant Sciences Ltd. • New York
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of May 14, 2021 (the “Effective Date”), by and between Roivant Sciences, Inc., a Delaware corporation (the “Company”), and Benjamin Zimmer, an individual (“Executive”) (hereinafter collectively referred to as the “Parties”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 14th, 2021 • Roivant Sciences Ltd. • New York
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of May 14, 2021 (the “Effective Date”), by and between Roivant Sciences, Inc., a Delaware corporation (the “Company”), and Eric Venker, an individual (“Executive”) (hereinafter collectively referred to as the “Parties”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 14th, 2021 • Roivant Sciences Ltd. • New York
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is hereby entered into as of May 14, 2021 (the “Effective Date”), by and between Roivant Sciences, Inc., a Delaware corporation (the “Company”), and Matthew Gline, an individual (“Executive”) (hereinafter collectively referred to as the “Parties”).
